Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives
- 1st Edition - October 1, 2020
- Imprint: Academic Press
- Editors: Jorge Morales-Montor, Mariana Segovia-Mendoza
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 2 0 2 8 - 3
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 0 2 9 - 0
Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interacti… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteImmunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping.
Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy.
- Provides basic and clinical evidence based on molecular interactions and clinical studies to address the risks and benefits of cancer immunotherapy
- Presents the results of new immunotherapy trials, discussing the state-of-the-art in different types of cancer
- Discusses targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies
Cancer researchers, medical scientists, clinicians, graduate students
- Cover image
- Title page
- Table of Contents
- Copyright
- Cover Figure Insert
- Aims and Scope for Series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy”
- About the Series Editor
- Aims and Scope of the Volume
- About the Volume Editors
- Affiliations and expertise
- Preface
- Contributors
- Chapter 1: Cancer vs immune tolerance—The challenge of fighting “self ”
- Abstract
- Introduction
- Mechanisms of immune tolerance
- Immune recognition of cancer. When only self is left
- Conclusion
- Chapter 2: Immunoconjugates as immune canoes to kill breast cancer cells
- Abstract
- Introduction
- Immunoconjugates
- Immunoconjugate structure
- Ims proved in breast cancer
- Conclusion
- Chapter 3: New intratumoral immunotherapeutic approaches to inhibit the tumor growth and metastasis in breast cancer
- Abstract
- Introduction
- Intratumoral injections
- Combined treatments
- New theoretical strategies
- Nanotechnology
- Conclusion
- Chapter 4: The Fas/FasL pathway as a target for enhancing anticancer adoptive cell therapy
- Abstract
- Introduction
- Non-specific cell therapies
- Specific cell therapies
- Conclusion
- Chapter 5: Harnessing metabolism for reinvigorating dysfunctional T cells in cancer
- Abstract
- Introduction
- Basics of metabolism
- Metabolic alterations observed in cancer-associated T cells
- Targeting metabolism for restoring anti-tumoral T cell responses
- Conclusion
- Chapter 6: The IgM as a tool for recognition of early tumoral antigens
- Abstract
- Introduction
- Natural IgM and breast cancer
- Conclusion
- Chapter 7: The inflammation during colorectal cancer: A friend or a foe?
- Abstract
- Introduction
- Acute inflammation has a physiological role in the colon
- The paradoxical role of inflammation between CAC and CRC
- Are either inflammatory bowel diseases or Th17 inflammatory pathway associated with CAC and CRC development?
- A paradox: protective role of inflammatory cytokines, transcription factors, and immune cells during CRC
- Inflammatory transcription factors involved in protection
- Inflammatory immune cells involved in protection
- Immunotherapy and chemotherapy in colon cancer
- Is the microbiota involved in the promotion of inflammation during CAC and CRC?
- Conclusion
- Chapter 8: Environmental pollution as a risk factor to develop colorectal cancer: The role of endocrine-disrupting chemicals in the inflammatory process as a risk factor to develop colorectal cancer
- Abstract
- Introduction
- Colorectal cancer and inflammation
- Immunoendocrine interaction in a context of inflammation
- Disrupting endocrine chemicals as a risk factor to develop colorectal cancer
- Conclusion
- Chapter 9: Targeting the STAT6 signaling pathway as a therapy against colon cancer
- Abstract
- Introduction
- STAT6 signaling pathway
- Dysregulation of STAT6 signaling in IBD and CRC
- Targeting STAT6 signaling to alter tumor progression
- Conclusion
- Chapter 10: Macrophage migration inhibitory factor (MIF): Its role in the genesis and progression of colorectal cancer
- Abstract
- Introduction
- Macrophage migration inhibitory factor (MIF)
- Biological structure of MIF
- MIF in the immune response
- MIF receptors
- Role of MIF in cancer genetics, development, and malignancy
- MIF as a chemokine involved in carrying effector immune cells against CRC
- Anti-MIF antibodies and inhibitors
- Conclusion
- Chapter 11: Fcγ receptors—Master regulators of antibody therapy
- Abstract
- Introduction
- Anticancer mAb mechanisms of action and resistance
- Therapeutic interventions to overcome FcγR-mediated resistance
- Conclusion
- Chapter 12: Novel immunotherapy strategies involving matrix metalloproteinase (MMP) family
- Abstract
- Introduction
- MMPs in cancer
- MMPs as targets in cancer therapy
- Conclusions
- Index
- Edition: 1
- Published: October 1, 2020
- No. of pages (Hardback): 286
- No. of pages (eBook): 286
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128220283
- eBook ISBN: 9780128220290
JM
Jorge Morales-Montor
Dr. Jorge Morales-Montor is the head of the Department of Neuroinmunoendocrinology at UNAM. In addition, at the moment he is the Editor in Chief of the journal Advances in Neuroimmune Biology. His laboratory has been interested in translational research and novel therapeutics in cancer, and other chronic degenerative diseases. He has expertise in leadership and training. Lately, he is focused on the immune alteration by endocrine disruptors in breast cancer.
Affiliations and expertise
Chair and head of Department of Neuroinmunoendocrinology, Institute of Biomedical Research, National Autonomous University of Mexico, (UNAM)MS
Mariana Segovia-Mendoza
Dr. Mariana Segovia Mendoza has extensive expertise in the subject of breast cancer and hormones. She also has collaborated with international groups. At the moment, she collaborates in the working lab group of Dr. Morales researching the infiltrating immune cells and their alterations by endocrine disruptor compounds in patients with breast cancer. Recently, she has published an article on this topic to expand the information as well as to accurately address different therapeutic options in an immuno-dependent manner.
Affiliations and expertise
Associate Professor, Departamento de Farmacologia, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, MexicoRead Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives on ScienceDirect